(HLUN-B) H Lundbeck - CO
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: CO (Denmark) | Market Cap: 42.901m DKK | Total Return: 17% in 12m
Avg Turnover: 31.6M
EPS Trend: 93.4%
Qual. Beats: 0
Rev. Trend: 99.2%
Qual. Beats: 1
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
H. Lundbeck A/S is a Denmark-based pharmaceutical company specializing in the research, development, and global commercialization of treatments for psychiatric and neurological disorders. Its primary product portfolio focuses on high-prevalence conditions including schizophrenia, major depressive disorder, migraine prevention, and Parkinson’s disease through brands such as Rexulti, Brintellix, and Vyepti.
The company operates within the CNS (central nervous system) therapeutic area, a sector characterized by high barriers to entry due to the physiological complexity of the blood-brain barrier and lengthy clinical trial cycles. Lundbeck utilizes a vertically integrated business model, managing the entire lifecycle of a drug from initial molecular research to large-scale manufacturing and international distribution.
Lundbeck maintains an active pipeline of small molecules and biologics, with several candidates in Phase 2 and Phase 3 clinical trials targeting cluster headaches and synucleinopathies. To mitigate the high R&D costs and technical risks inherent in drug development, the firm employs strategic research collaborations, such as its partnership with Contera Pharma for oligonucleotide-based medicines.
- Rexulti and Vyepti sales growth offsets legacy product patent erosion
- R&D pipeline advancement in migraine and neuro-immunology drives valuation
- Strategic acquisitions like Longboard Pharmaceuticals diversify neurology portfolio and pipeline
- US market revenue concentration exposes margins to drug pricing reform
| Net Income: 3.70b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 3.78 > 1.0 |
| NWC/Revenue: 14.54% < 20% (prev 18.57%; Δ -4.02% < -1%) |
| CFO/TA 0.09 > 3% & CFO 4.87b > Net Income 3.70b |
| Net Debt (9.45b) to EBITDA (9.32b): 1.01 < 3 |
| Current Ratio: 1.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (992.4m) vs 12m ago 0.05% < -2% |
| Gross Margin: 78.95% > 18% (prev 81.06%; Δ -2.11% > 0.5%) |
| Asset Turnover: 47.20% > 50% (prev 42.38%; Δ 4.82% > 0%) |
| Interest Coverage Ratio: 11.75 > 6 (EBIT TTM 7.00b / Interest Expense TTM 596.0m) |
| A: 0.07 (Total Current Assets 12.6b - Total Current Liabilities 8.99b) / Total Assets 52.3b |
| B: 0.48 (Retained Earnings 25.1b / Total Assets 52.3b) |
| C: 0.13 (EBIT TTM 7.00b / Avg Total Assets 53.3b) |
| D: 0.96 (Book Value of Equity 25.6b / Total Liabilities 26.7b) |
| Altman-Z'' = 3.91 = AA |
| DSRI: 1.04 (Receivables 6.09b/5.35b, Revenue 25.1b/23.0b) |
| GMI: 1.03 (GM 81.06% / 78.95%) |
| AQI: 0.97 (AQ_t 0.70 / AQ_t-1 0.72) |
| SGI: 1.09 (Revenue 25.1b / 23.0b) |
| TATA: -0.02 (NI 3.70b - CFO 4.87b) / TA 52.3b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of June 20, 2026, the stock is trading at DKK 41.52 with a total of 863,102 shares traded.
Over the past week, the price has changed by -4.99%,
over one month by +3.39%,
over three months by +11.79% and
over the past year by +16.98%.
H Lundbeck has no consensus analysts rating.
P/E Trailing = 11.5
P/E Forward = 11.4416
P/S = 1.6811
P/B = 1.6745
P/EG = 8.0471
Revenue TTM = 25.1b DKK
EBIT TTM = 7.00b DKK
EBITDA TTM = 9.32b DKK
Long Term Debt = 10.4b DKK (from longTermDebt, last quarter)
Short Term Debt = 74.0m DKK (from shortTermDebt, last quarter)
Debt = 11.4b DKK (from shortLongTermDebtTotal, last quarter) + Leases 482.0m
Net Debt = 9.45b DKK (calculated: Debt 11.4b - CCE 1.96b)
Enterprise Value = 52.4b DKK (42.9b + Debt 11.4b - CCE 1.96b)
Interest Coverage Ratio = 11.75 (Ebit TTM 7.00b / Interest Expense TTM 596.0m)
EV/FCF = 12.16x (Enterprise Value 52.4b / FCF TTM 4.31b)
FCF Yield = 8.22% (FCF TTM 4.31b / Enterprise Value 52.4b)
FCF Margin = 17.13% (FCF TTM 4.31b / Revenue TTM 25.1b)
Net Margin = 14.71% (Net Income TTM 3.70b / Revenue TTM 25.1b)
Gross Margin = 78.95% ((Revenue TTM 25.1b - Cost of Revenue TTM 5.29b) / Revenue TTM)
Gross Margin QoQ = 80.03% (prev 66.43%)
Tobins Q-Ratio = 1.00 (Enterprise Value 52.4b / Total Assets 52.3b)
Interest Expense / Debt = 5.22% (Interest Expense 596.0m / Debt 11.4b)
Taxrate = 28.00% (1.44b / 5.14b)
NOPAT = 5.04b (EBIT 7.00b * (1 - 28.00%))
Current Ratio = 1.41 (Total Current Assets 12.6b / Total Current Liabilities 8.99b)
Debt / Equity = 0.45 (Debt 11.4b / totalStockholderEquity, last quarter 25.6b)
Debt / EBITDA = 1.01 (Net Debt 9.45b / EBITDA 9.32b)
Debt / FCF = 2.20 (Net Debt 9.45b / FCF TTM 4.31b)
Total Stockholder Equity = 25.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.94% (Net Income 3.70b / Total Assets 52.3b)
RoE = 14.81% (Net Income TTM 3.70b / Total Stockholder Equity 25.0b)
RoCE = 19.78% (EBIT 7.00b / Capital Employed (Equity 25.0b + L.T.Debt 10.4b))
RoIC = 11.97% (NOPAT 5.04b / Invested Capital 42.1b)
WACC = 7.20% (E(42.9b)/V(54.3b) * Re(8.12%) + D(11.4b)/V(54.3b) * Rd(5.22%) * (1-Tc(0.28)))
Discount Rate = 8.12% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 17.98 | Cagr: 0.02%
[DCF] Terminal Value 77.97% ; FCFF base≈3.55b ; Y1≈4.07b ; Y5≈5.99b
[DCF] Fair Price = 101.7 (EV 90.1b - Net Debt 9.45b = Equity 80.7b / Shares 793.1m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 93.39 | EPS CAGR: 24.26% | SUE: -0.83 | # QB: 0
Revenue Correlation: 99.25 | Revenue CAGR: 10.67% | SUE: 1.73 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.48 | Chg30d=-0.33% | Revisions=-14% | Analysts=4
EPS next Quarter (2026-09-30): EPS=1.49 | Chg30d=-0.35% | Revisions=-43% | Analysts=4
EPS current Year (2026-12-31): EPS=6.30 | Chg30d=+1.63% | Revisions=+64% | GrowthEPS=+19.8% | GrowthRev=+4.4%
EPS next Year (2027-12-31): EPS=6.12 | Chg30d=+0.96% | Revisions=+27% | GrowthEPS=-2.8% | GrowthRev=+0.1%
[Analyst] Revisions Ratio: +64%